[1]王文重,伊 扬,董晓昕,等.食管癌患者新辅助化疗前后生理指标变化及意义[J].医学信息,2022,35(09):116-119.[doi:10.3969/j.issn.1006-1959.2022.09.029]
　WANG Wen-zhong,YI Yang,DONG Xiao-xin,et al.Changes and Significance of Physiological Indexes in Esophageal Cancer Patients Before and After Neoadjuvant Chemotherapy[J].Medical Information,2022,35(09):116-119.[doi:10.3969/j.issn.1006-1959.2022.09.029]
点击复制

食管癌患者新辅助化疗前后生理指标变化及意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年09期
页码:
116-119
栏目:
论著
出版日期:
2022-05-01

文章信息/Info

Title:
Changes and Significance of Physiological Indexes in Esophageal Cancer Patients Before and After Neoadjuvant Chemotherapy
文章编号:
1006-1959（2022）09-0116-04
作者:
王文重; 伊 扬; 董晓昕; 等
（北京市朝阳区桓兴肿瘤医院肿瘤内科，北京 100123）
Author(s):
WANG Wen-zhong; YI Yang; DONG Xiao-xin; et al.
(Department of Oncology,Cancer Hospital of Huanxing,Chaoyang District,Beijing 100123,China)
关键词:
食管恶性肿瘤; 新辅助化疗; 肿瘤消退; 生理指标
Keywords:
Malignant esophageal tumor; Neoadjuvant chemotherapy; Tumor regression; Physiological indicators
分类号:
R735.1
DOI:
10.3969/j.issn.1006-1959.2022.09.029
文献标志码:
A
摘要:
目的 探讨食管癌新辅助化疗前后的生理指标变化及临床意义。方法 收集我院2017年1月-2020年2月经过新辅助化疗（NAC）后手术切除的局部晚期食管癌及食管胃交接性腺癌或鳞癌患者104例资料，比较血清营养学指标、血清炎性指标、血清免疫学指标、肿瘤标志物等指标在接受NAC前后的差异。结果 28例患者肿瘤中度/完全消退（26.92%）、25例患者肿瘤轻度消退（24.04%）、51例患者肿瘤未见明显消退（49.04%）；食管癌患者新辅助化疗后血清营养学指标（血红蛋白、白蛋白、总蛋白）、血清炎性指标（白细胞、中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值）均低于化疗前，差异有统计学意义（P＜0.05）；在食管癌患者NAC不同疗效组血清营养学指标、炎性指标均低于化疗前，差异有统计学意义（P＜0.05）；不同治疗方案的食管癌患者IgG、IgA、CEA、CA242均低于治疗前，差异有统计学意义（P＜0.05）。结论 食管癌患者在接受NAC后血清营养指标、炎性指标等指标明显降低，应关注中晚期食管癌患者在接受NAC治疗后营养水平和炎性指标变化，为患者接受下一步治疗提供临床证据。
Abstract:
Objective To investigate the changes and clinical significance of physiological indexes before and after neoadjuvant chemotherapy for esophageal cancer.Methods The data of 104 patients with locally advanced esophageal cancer and esophagogastric junction adenocarcinoma or squamous cell carcinoma who underwent surgical resection after neoadjuvant chemotherapy (NAC) in our hospital from January 2017 to February 2020 were collected. The differences of serum nutritional indexes, serum inflammatory indexes, serum immunological indexes and tumor markers before and after NAC were compared.Results A total of 28 patients had moderate/complete regression (26.92%), 25 patients had mild regression (24.04%), and 51 patients had no significant regression (49.04%). The serum nutritional indexes (hemoglobin, albumin, total protein) and serum inflammatory indexes (leukocyte, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio) in patients with esophageal cancer after neoadjuvant chemotherapy were lower than those before chemotherapy, the difference was statistically significant (P<0.05). The serum nutritional and inflammatory indexes of patients with esophageal cancer in NAC groups with different therapeutic effects were lower than those before chemotherapy, and the difference was statistically significant (P<0.05). IgG, IgA, CEA and CA242 of esophageal cancer patients with different treatment regimens were lower than those before treatment, and the difference was statistically significant (P<0.05).Conclusion The serum nutritional index and inflammatory index of patients with esophageal cancer after receiving NAC are significantly reduced. Attention should be paid to the changes in nutritional level and inflammatory index of patients with advanced esophageal cancer after receiving NAC treatment, so as to provide clinical evidence for patients to receive the next treatment.

参考文献/References:

[1]GBD 2017 Pancreatic Cancer Collaborators.The global,regional,and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet Gastroenterol Hepatol,2019,4(12):934-947.[2]Fitzmaurice C,Abate D,Abbasi N,et al.Global,Regional,and National Cancer Incidence,Mortality,Years of Life Lost,Years Lived With Disability,and Disability-Adjusted Life-Years for 29 Cancer Groups,1990 to 2017:A Systematic Analysis for the Global Burden of Disease Study[J].JAMA Oncol,2019,5(12):1749-1768.[3]毛友生,高树庚,王群,等.中国食管癌临床流行特征及外科治疗概况大数据分析[J].中华肿瘤杂志2020,42(3):228-233.[4]陈茹,郑荣寿,张思维,等.2015年中国食管癌发病和死亡情况分析[J].中华预防医学杂志,2019,53(11):1094-1097.[5]Yang H,Liu H,Chen Y,et al.Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus(NEOCRTEC5010):A Phase Ⅲ Multicenter,Randomized,Open-Label Clinical Trial[J].Journal of Clinical Oncology,2018,36(27):2796-2803.[6]郑浩,汪灏,唐汉,等.新辅助同步放化疗与新辅助化疗治疗局部进展期食管鳞癌的疗效分析[J]. 中华消化外科杂志, 2017,16(5):464-468.[7]蔺军平,李政,尹泚,等.超声内镜在食管癌临床TN分期诊断中的应用价值[J].中华实用诊断与治疗杂志,2019,33(10):1008-1010.[8]左婷婷,郑荣寿,曾红梅,等.中国食管癌发病状况与趋势分析[J].中华肿瘤杂志,2016,38(9):703-708.[9]樊宁波,陈冬妮,温浙盛,等.术前血浆白蛋白与纤维蛋白原比值对食管鳞癌根治术后生存的预测价值[J].中华消化外科杂志,2019,18(6):563-569.[10]王晓凝,郝志芬.食管癌围手术期肠内营养支持对患者血红蛋白,血浆白蛋白水平及淋巴细胞计数的影响[J].中国卫生标准管理,2016,7(4):1-2.[11]徐晓霞,王昆仑,刘杨,等.血清白蛋白对食管癌放疗患者生存时间的影响[J].中国实用医刊,2016,43(16):17-19.[12]宋春洋,祝淑钗,沈文斌,等.临床Ⅲ期食管癌患者放疗前后免疫功能及外周血炎症指标对预后的影响分析[J].中华放射医学与防护杂志,2020,40(3):189-195.[13]熊凯,肖何,郑继军,等.中性粒细胞-淋巴细胞比值对食管鳞状细胞癌术前新辅助放化疗效果的预测价值[J].第三军医大学学报,2021,43(2):168-174.[14]袁俊,李印,彭银杰,等.术前中性粒细胞与淋巴细胞比值对淋巴结转移的胸段食管鳞癌病人预后的预测价值[J].临床外科杂志,2020,28(7):627-630.[15]李国雨,何明,李国庆.新辅助治疗对食管癌患者手术前后营养状况的影响[J].中华胸部外科电子杂志,2019,6(4):239-242.[16]范诚诚,冯卓,葛红,等.新辅助治疗联合手术治疗后复发食管鳞癌再程治疗的预后分析[J].中华放射肿瘤学杂志,2020,29(1):26-30.[17]王胜,开金丹,徐元涛,等.新辅助化疗对老年食管癌手术患者免疫功能及残端癌发生率的影响[J].武汉大学学报(医学版),2014,35(5):704-706,726.

相似文献/References:

[1]屈欣然.DCE-MRI对局部进展期乳腺癌新辅助化疗的临床指导价值研究[J].医学信息,2018,31(04):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
　QU Xin-ran.Clinical Value of DCE-MRI in Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer[J].Medical Information,2018,31(09):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
[2]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
　ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Medical Information,2022,35(09):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[3]苏 志,吴 蔚,吴智钢,等.含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察[J].医学信息,2018,31(21):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
　SU Zhi,WU Wei,WU Zhi-gang,et al.Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for OsteosarcomaC[J].Medical Information,2018,31(09):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
[4]王绥能,梁贤文,孙 光,等.伊立替康新辅助化疗在进展期胃癌的临床意义[J].医学信息,2018,31(24):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]
　WANG Sui-neng,LIANG Xian-wen,SUN Guang,et al.Clinical Significance of Irinotecan Neoadjuvant Chemotherapy in Advanced Gastric Carcinoma[J].Medical Information,2018,31(09):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]
[5]黄 雨,楼浩男,涂 刚.Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析[J].医学信息,2019,32(04):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
　HUANG Yu,LOU Hao-nan,TU Gang.Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer[J].Medical Information,2019,32(09):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
[6]李 博,李春晓.新辅助化疗在宫颈癌治疗中的应用[J].医学信息,2019,32(15):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
　LI Bo,LI Chun-xiao.Application of Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer[J].Medical Information,2019,32(09):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
[7]关利平,李建文.凝血相关指标与乳腺癌新辅助化疗疗效预测的相关性研究[J].医学信息,2022,35(16):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
　GUAN Li-ping,LI Jian-wen.Study on Correlation Between Coagulation- related Indexes and Efficacy Prediction of Neoadjuvant Chemotherapy for Breast Cancer[J].Medical Information,2022,35(09):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
[8]付大鹏.多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果[J].医学信息,2020,33(05):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
　FU Da-peng.Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer[J].Medical Information,2020,33(09):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
[9]王羽翎,孙佳威,周显礼.二维及三维实时剪切波弹性成像在乳腺肿块评估中的应用[J].医学信息,2020,33(11):42.[doi:10.3969/j.issn.1006-1959.2020.11.014]
　WANG Yu-ling,SUN Jia-wei,ZHOU Xian-li.Application of 2D and 3D Real-time Shear Wave Elastography in Breast Mass Evaluation[J].Medical Information,2020,33(09):42.[doi:10.3969/j.issn.1006-1959.2020.11.014]
[10]周靖宇,单慧明,成官迅.基于支持向量机的全乳纹理分析预测乳腺癌新辅助化疗疗效的价值[J].医学信息,2022,35(19):60.[doi:10.3969/j.issn.1006-1959.2022.19.016]
　ZHOU Jing-yu,SHAN Hui-ming,CHENG Guan-xun.Prediction of Neoadjuvant Chemotherapy Outcomes of Breast Cancer Based on Whole Breast Texture with Support Vector Machine[J].Medical Information,2022,35(09):60.[doi:10.3969/j.issn.1006-1959.2022.19.016]

更新日期/Last Update: 1900-01-01